Literature DB >> 22811845

The role of epithelial-mesenchymal transition in pancreatic cancer.

Jen-Jung Pan1, Muh-Hwa Yang.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer related death in the US. Despite the advances in medical and surgical treatment, the 5-year survival rate for such cancer is only approximately 5% when considering all stages of disease. The lethal nature of pancreatic cancer stems from its high metastatic potential to the lymphatic system and distant organs. Lack of effective chemotherapies, which is believed to be due to drug-resistance, also contributes to the high mortality of pancreatic cancer. Recent evidence suggests that epithelial-mesenchymal transition of pancreatic cancer cells contributes to the development of drug resistance and an increase in invasiveness. Future strategies that specifically target against epithelial-mesenchymal transition phenotype could potentially reduce tumoral drug resistance and invasiveness and hence prolong the survival of patients with pancreatic cancer.

Entities:  

Keywords:  cancer stem cell; epithelial-mesenchymal transition; pancreatic cancer

Year:  2011        PMID: 22811845      PMCID: PMC3397615          DOI: 10.3978/j.issn.2078-6891.2011.022

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  54 in total

1.  Evidence for a function of CtBP in epithelial gene regulation and anoikis.

Authors:  M L Grooteclaes; S M Frisch
Journal:  Oncogene       Date:  2000-08-03       Impact factor: 9.867

Review 2.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

3.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 4.  Pancreatic cancer.

Authors:  Theresa Pluth Yeo; Ralph H Hruban; Steven D Leach; Robb E Wilentz; Taylor A Sohn; Scott E Kern; Christine A Iacobuzio-Donahue; Anirban Maitra; Michael Goggins; Marcia I Canto; Ross A Abrams; Daniel Laheru; Elizabeth M Jaffee; Manuel Hidalgo; Charles J Yeo
Journal:  Curr Probl Cancer       Date:  2002 Jul-Aug       Impact factor: 3.187

5.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.

Authors:  J Comijn; G Berx; P Vermassen; K Verschueren; L van Grunsven; E Bruyneel; M Mareel; D Huylebroeck; F van Roy
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

6.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 7.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

Review 8.  CCN proteins: multifunctional signalling regulators.

Authors:  Bernard Perbal
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

9.  Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex.

Authors:  Hector Peinado; Esteban Ballestar; Manel Esteller; Amparo Cano
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

View more
  16 in total

1.  JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Anbing Dong; Jianpeng Fan; Kejian Guo; Yuanhong Xu
Journal:  Tumour Biol       Date:  2012-04-27

2.  Twist expression associated with the epithelial-mesenchymal transition in gastric cancer.

Authors:  Ai-ning Liu; Zhi-Hua Zhu; Shu-jian Chang; Xiao-sheng Hang
Journal:  Mol Cell Biochem       Date:  2012-05-13       Impact factor: 3.396

3.  Pancreatic cancer: current standards, research updates and future directions.

Authors:  Chung-Tsen Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

4.  Activation of β-catenin signaling is critical for doxorubicin-induced epithelial-mesenchymal transition in BGC-823 gastric cancer cell line.

Authors:  Rongfei Han; Jie Xiong; Ruijing Xiao; Ehtisham Altaf; Jin Wang; Yanping Liu; Hui Xu; Qianshan Ding; Qiuping Zhang
Journal:  Tumour Biol       Date:  2012-10-10

5.  Neoadjuvant treatment for resectable pancreatic adenocarcinoma.

Authors:  John Wong; Naveenraj L Solomon; Chung-Tsen Hsueh
Journal:  World J Clin Oncol       Date:  2016-02-10

6.  Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Authors:  Liu Yang; Mei Liu; Chuanzong Deng; Zhikai Gu; Yilu Gao
Journal:  Tumour Biol       Date:  2012-04-29

7.  Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.

Authors:  Kaja Lund; Jennifer L Dembinski; Nina Solberg; Alfonso Urbanucci; Ian G Mills; Stefan Krauss
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

8.  Circulating TGF-β1 as the potential epithelial mesenchymal transition-biomarker for diagnosis of cholangiocarcinoma.

Authors:  Phongsaran Kimawaha; Apinya Jusakul; Prem Junsawang; Watcharin Loilome; Narong Khuntikeo; Anchalee Techasen
Journal:  J Gastrointest Oncol       Date:  2020-04

9.  Epimorphin-induced MET sensitizes ovarian cancer cells to platinum.

Authors:  Kok-Hooi Yew; Jennifer Crow; Jeff Hirst; Ziyan Pessetto; Ziyan Pressetto; Andrew K Godwin
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516.

Authors:  Kazuya Arai; Takanori Eguchi; M Mamunur Rahman; Ruriko Sakamoto; Norio Masuda; Tetsuya Nakatsura; Stuart K Calderwood; Ken-Ichi Kozaki; Manabu Itoh
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.